Submission of Financials as on 30.06.2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 04 Aug 2026, 06:12 PM IST · BSE ID: 54c03024-e134-44f9-8e44-92c476d80d0e
View Original BSE Filing (PDF)
💡
In Simple Terms
Sudeep Pharma announced its latest financial results, showing an increase in quarterly profit and revenue.
🤖 AI Summary
- Sudeep Pharma's consolidated net profit for Q1 FY27 increased to Rs. 4,058.69 Lakhs.
- Consolidated revenue from operations for the quarter ended June 30, 2026, was Rs. 15,827.05 Lakhs.
- The Board of Directors approved unaudited standalone and consolidated financial results.
- The company's equity shares were listed on NSE and BSE on November 28, 2025.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations
Rs. 15,827.05 Lakhs
26.70%
Consolidated Profit for the period
Rs. 4,058.69 Lakhs
29.80%
Consolidated Basic EPS
Rs. 3.59
26.41%
Unutilised Net IPO Proceeds for Capital Expenditure
Rs. 7,545.63 Lakhs
🏢 How This Affects the Company
Consolidated revenue from operations for the Pharmaceutical, food and nutrition segment was Rs. 10,841.37 Lakhs, while the Speciality ingredients segment generated Rs. 4,985.68 Lakhs in Q1 FY27.
Profit for the period on a consolidated basis reached Rs. 4,058.69 Lakhs, up from Rs. 3,126.92 Lakhs in the prior comparable period. Basic Earnings per Equity Share increased to Rs. 3.59 from Rs. 2.84.
The financial results include unaudited financial results of two subsidiaries reflecting total revenues of Rs. 1,139.55 Lakhs and total net loss of Rs. 49.12 Lakhs for the quarter, which are considered not material by management.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the 29.80% increase in profit and basic EPS rising from Rs. 2.84 to Rs. 3.59.
🔍
Management Signal
The Board's approval of the unaudited financial results signals regular compliance and reporting of the company's performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — assess sustained revenue and profit growth.
Updates on deployment of Rs. 7,545.63 Lakhs unutilised IPO proceeds.
Segment-wise performance of Pharmaceutical and Speciality ingredients in subsequent quarters.
LOW RISK
The limited review report notes two unreviewed subsidiaries, but management considers their financial results not material.
💡 Investor Takeaway
Sudeep Pharma reported a consolidated profit for Q1 FY27 of Rs. 4,058.69 Lakhs, a 29.80% increase from Rs. 3,126.92 Lakhs in Q1 FY26. Consolidated revenue from operations grew 26.70% to Rs. 15,827.05 Lakhs from Rs. 12,491.75 Lakhs in the prior year.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Profit for the period increased by 29.80% to Rs. 4,058.69 Lakhs for Q1 FY27 compared to Q1 FY26.
- Revenue from operations grew by 26.70% to Rs. 15,827.05 Lakhs for Q1 FY27 over the previous year's corresponding quarter.
⚠️ Concerns
- Unutilised net IPO proceeds for capital expenditure totaled Rs. 7,545.63 Lakhs as of June 30, 2026.
- Consolidated Other Comprehensive income/(loss) for the period was negative Rs. 5.21 Lakhs in Q1 FY27.
📅 Company Track Record
Sudeep Pharma Ltd. was recently listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on November 28, 2025. Past filings indicate a Q1 FY27 net profit increase of 29.80% YoY to Rs. 4,058.69 Lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Sudeep Pharma's consolidated net profit for Q1 FY27?
Sudeep Pharma's consolidated net profit for the first quarter ended June 30, 2026, was Rs. 4,058.69 Lakhs.
What was Sudeep Pharma's consolidated revenue from operations in Q1 FY27?
Consolidated revenue from operations for Sudeep Pharma in Q1 FY27 was Rs. 15,827.05 Lakhs.
How did Sudeep Pharma's profit compare to the same quarter last year?
Consolidated profit for the period increased to Rs. 4,058.69 Lakhs in Q1 FY27 from Rs. 3,126.92 Lakhs in Q1 FY26, representing a 29.80% increase.
When was Sudeep Pharma Limited listed on the stock exchanges?
Sudeep Pharma Limited's equity shares were listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE) on November 28, 2025.
What is the status of Sudeep Pharma's IPO proceeds as of June 30, 2026?
As of June 30, 2026, Sudeep Pharma had unutilised net IPO proceeds of Rs. 7,545.63 Lakhs designated for capital expenditure, which are held as term deposits.
Questions based on this BSE filing only. For information purposes.